armata pharmaceuticals - ARMP

ARMP

Close Chg Chg %
6.23 0.03 0.48%

Closed Market

6.26

+0.03 (0.48%)

Volume: 7.53K

Last Updated:

Dec 31, 2025, 3:59 PM EDT

Company Overview: armata pharmaceuticals - ARMP

ARMP Key Data

Open

$6.08

Day Range

6.08 - 6.34

52 Week Range

0.90 - 16.34

Market Cap

$227.18M

Shares Outstanding

36.41M

Public Float

10.99M

Beta

1.25

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.30

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

42.99K

 

ARMP Performance

1 Week
 
-4.56%
 
1 Month
 
-14.32%
 
3 Months
 
101.28%
 
1 Year
 
239.46%
 
5 Years
 
110.39%
 

ARMP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About armata pharmaceuticals - ARMP

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

ARMP At a Glance

Armata Pharmaceuticals, Inc.
5005 McConnell Avenue
Los Angeles, California 90066
Phone 1-310-655-2928 Revenue 5.17M
Industry Biotechnology Net Income -18,916,000.00
Sector Health Technology 2024 Sales Growth 14.242%
Fiscal Year-end 12 / 2025 Employees 60
View SEC Filings

ARMP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 12.93
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.479
Enterprise Value to Sales 35.586
Total Debt to Enterprise Value 0.687

ARMP Efficiency

Revenue/Employee 86,233.333
Income Per Employee -315,266.667
Receivables Turnover 6.954
Total Asset Turnover 0.049

ARMP Liquidity

Current Ratio 0.234
Quick Ratio 0.234
Cash Ratio 0.193

ARMP Profitability

Gross Margin 74.391
Operating Margin -820.178
Pretax Margin -365.597
Net Margin -365.597
Return on Assets -18.076
Return on Equity N/A
Return on Total Capital -24.098
Return on Invested Capital -33.205

ARMP Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 161.174
Total Debt to Total Assets 127.366
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 105.903
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Armata Pharmaceuticals - ARMP

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
4.47M 5.51M 4.53M 5.17M
Sales Growth
+443.62% +23.11% -17.77% +14.24%
Cost of Goods Sold (COGS) incl D&A
- 892.00K 972.00K 1.32M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.17M 892.00K 972.00K 1.32M
Depreciation
1.17M 892.00K 972.00K 1.32M
Amortization of Intangibles
- - - -
-
COGS Growth
- - +8.97% +36.32%
-
Gross Income
- 4.62M 3.56M 3.85M
Gross Income Growth
- - -22.94% +8.21%
-
Gross Profit Margin
- +83.81% +78.54% +74.39%
2021 2022 2023 2024 5-year trend
SG&A Expense
27.13M 41.56M 44.45M 46.28M
Research & Development
20.02M 35.02M 33.77M 34.43M
Other SG&A
7.11M 6.54M 10.68M 11.86M
SGA Growth
+27.38% +53.21% +6.94% +4.14%
Other Operating Expense
- - - -
-
Unusual Expense
- (726.00K) 25.71M (33.56M)
EBIT after Unusual Expense
(23.10M) (36.95M) (66.60M) (8.87M)
Non Operating Income/Expense
5.00K 29.00K 179.00K 697.00K
Non-Operating Interest Income
5.00K 29.00K 179.00K 697.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 64.00K 2.63M 10.74M
Interest Expense Growth
- -89.81% -100.00% +309.06%
Gross Interest Expense
- 64.00K 2.63M 10.74M
Interest Capitalized
- - - -
-
Pretax Income
(23.16M) (36.92M) (69.05M) (18.92M)
Pretax Income Growth
-4.39% -59.43% -87.03% +72.60%
Pretax Margin
-517.55% -670.24% -1,524.51% -365.60%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(23.16M) (36.92M) (69.05M) (18.92M)
Minority Interest Expense
- - - -
-
Net Income
(23.16M) (36.92M) (69.05M) (18.92M)
Net Income Growth
-4.39% -59.43% -87.03% +72.60%
Net Margin Growth
-517.55% -670.24% -1,524.51% -365.60%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(23.16M) (36.92M) (69.05M) (18.92M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(23.16M) (36.92M) (69.05M) (18.92M)
EPS (Basic)
-0.9606 -1.0765 -1.9139 -0.5231
EPS (Basic) Growth
+28.91% -12.07% -77.79% +72.67%
Basic Shares Outstanding
24.10M 34.29M 36.08M 36.16M
EPS (Diluted)
-0.9606 -1.0765 -1.9139 -0.5231
EPS (Diluted) Growth
+28.91% -12.07% -77.79% +72.67%
Diluted Shares Outstanding
24.10M 34.29M 36.08M 36.16M
EBITDA
(22.65M) (36.05M) (39.92M) (41.11M)
EBITDA Growth
-10.65% -59.16% -10.72% -2.99%
EBITDA Margin
-506.33% -654.58% -881.39% -794.57%

Snapshot

Average Recommendation BUY Average Target Price 9.00
Number of Ratings 1 Current Quarters Estimate -0.19
FY Report Date 12 / 2025 Current Year's Estimate -1.54
Last Quarter’s Earnings -0.74 Median PE on CY Estimate N/A
Year Ago Earnings -0.89 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 N/A 1 N/A
Mean Estimate -0.19 N/A -1.54 N/A
High Estimates -0.19 N/A -1.54 N/A
Low Estimate -0.19 N/A -1.54 N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Armata Pharmaceuticals in the News